D.H. Coy

9.7k total citations · 2 hit papers
238 papers, 7.9k citations indexed

About

D.H. Coy is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, D.H. Coy has authored 238 papers receiving a total of 7.9k indexed citations (citations by other indexed papers that have themselves been cited), including 115 papers in Molecular Biology, 112 papers in Cellular and Molecular Neuroscience and 73 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in D.H. Coy's work include Neuropeptides and Animal Physiology (109 papers), Receptor Mechanisms and Signaling (73 papers) and Growth Hormone and Insulin-like Growth Factors (47 papers). D.H. Coy is often cited by papers focused on Neuropeptides and Animal Physiology (109 papers), Receptor Mechanisms and Signaling (73 papers) and Growth Hormone and Insulin-like Growth Factors (47 papers). D.H. Coy collaborates with scholars based in United States, United Kingdom and Canada. D.H. Coy's co-authors include Andrew V. Schally, Abba J. Kastin, G. M. Besser, R. Hall, John E. Taylor, W Rossowski, Robert T. Jensen, William A. Murphy, Ashley Grossman and A Gómez-Pan and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Biological Chemistry.

In The Last Decade

D.H. Coy

234 papers receiving 7.3k citations

Hit Papers

INHIBITION OF GASTRIN AND... 1974 2026 1991 2008 1974 1974 100 200 300 400

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
D.H. Coy 3.5k 3.3k 2.6k 1.6k 1.5k 238 7.9k
A Enjalbert 2.7k 0.8× 1.7k 0.5× 3.8k 1.5× 1.2k 0.8× 1.5k 1.0× 208 7.4k
Roger Burgus 2.1k 0.6× 1.6k 0.5× 1.8k 0.7× 712 0.4× 1.2k 0.8× 58 5.5k
Michael D. Culler 2.8k 0.8× 2.1k 0.7× 3.9k 1.5× 1.5k 1.0× 3.2k 2.1× 194 10.0k
Lawrence A. Frohman 2.3k 0.7× 1.0k 0.3× 5.4k 2.1× 1.4k 0.9× 802 0.5× 206 9.6k
Reiner Fischer‐Colbrie 5.1k 1.5× 4.0k 1.2× 630 0.2× 1.0k 0.6× 864 0.6× 208 9.2k
Patrick Robberecht 5.3k 1.5× 5.8k 1.8× 1.3k 0.5× 2.1k 1.3× 716 0.5× 314 9.3k
Marc Laburthe 6.3k 1.8× 7.0k 2.1× 1.3k 0.5× 1.8k 1.1× 549 0.4× 218 10.9k
Keith L. Parker 5.3k 1.5× 835 0.3× 1.8k 0.7× 1.2k 0.8× 473 0.3× 100 10.5k
M.A. Ghatei 2.0k 0.6× 3.5k 1.1× 802 0.3× 1.3k 0.8× 355 0.2× 89 5.6k
Haruo Onda 2.4k 0.7× 4.2k 1.3× 1.2k 0.5× 2.6k 1.6× 593 0.4× 76 8.6k

Countries citing papers authored by D.H. Coy

Since Specialization
Citations

This map shows the geographic impact of D.H. Coy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D.H. Coy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D.H. Coy more than expected).

Fields of papers citing papers by D.H. Coy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D.H. Coy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D.H. Coy. The network helps show where D.H. Coy may publish in the future.

Co-authorship network of co-authors of D.H. Coy

This figure shows the co-authorship network connecting the top 25 collaborators of D.H. Coy. A scholar is included among the top collaborators of D.H. Coy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D.H. Coy. D.H. Coy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Heer, Jocelyn de, C.E. Rasmussen, D.H. Coy, & Jens J. Holst. (2008). Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia. 51(12). 2263–2270. 191 indexed citations
2.
Ito, Tetsuhide, Hisato Igarashi, Tapas K. Pradhan, et al.. (2001). GI side-effects of a possible therapeutic GRF analogue in monkeys are likely due to VIP receptor agonist activity. Peptides. 22(7). 1139–1151. 11 indexed citations
3.
Malik, Meenakshi, et al.. (1997). Immunomodulatory activities of the somatostatin receptor subtype analogues on human peripheral blood lymphocytes. Transplantation Proceedings. 29(4). 2151–2151. 7 indexed citations
4.
Weigert, N., et al.. (1997). Role of vagal fibers and bombesin/gastrin-releasing peptide-neurons in distention-induced gastrin release in rats. Regulatory Peptides. 69(1). 33–40. 16 indexed citations
5.
Champion, Hunter C., Marc A. Czapla, David G. Lambert, et al.. (1997). Tone-Dependent Vasodilator Responses to Proadrenomedullin NH2-Terminal 20 Peptide in the Hindquarters Vascular Bed of the Rat. Peptides. 18(4). 513–519. 19 indexed citations
6.
Champion, Hunter C., et al.. (1997). Adrenomedullin(16–31) Has Pressor Activity in the Rat But Not the Cat. Peptides. 18(1). 133–136. 16 indexed citations
7.
Champion, Hunter C., et al.. (1996). Proadrenomedullin NH2-terminal 20 peptide has cAMP-mediated vasodilator activity in the mesenteric vascular bed of the cat. Peptides. 17(8). 1379–1387. 17 indexed citations
9.
Mahmoud, Soliman A., Julie K. Staley, John E. Taylor, et al.. (1991). [Psi 13,14] bombesin analogues inhibit growth of small cell lung cancerin vitro and in vivo.. PubMed. 51(7). 1798–802. 140 indexed citations
10.
Staley, Julie K., et al.. (1991). [Des-Met14]Bombesin analogues function as small cell lung cancer bombesin receptor antagonists. Peptides. 12(1). 145–149. 24 indexed citations
11.
Yağcı, Ramazan, et al.. (1991). Galanin inhibits pancreatic amylase secretion in the pentobarbital-anesthetized rat. Regulatory Peptides. 34(3). 275–282. 14 indexed citations
12.
Grossman, A., N. Lytras, M O Savage, et al.. (1984). Growth hormone releasing factor: comparison of two analogues and demonstration of hypothalamic defect in growth hormone release after radiotherapy.. BMJ. 288(6433). 1785–1787. 29 indexed citations
13.
McLoughlin, Lorraine, Susan Tomlin, Ashley Grossman, et al.. (1984). CRF-41 Stimulates the Release of β-Lipotrophin and β-Endorphin in Normal Human Subjects. Neuroendocrinology. 38(4). 282–284. 26 indexed citations
14.
Arimura, Akira, G. Lundqvist, Robert C. Chang, et al.. (1978). Radioimmunoassay of somatostatin. Metabolism. 27(9). 1139–1144. 142 indexed citations
15.
Coy, D.H., et al.. (1976). Suppression of LH-RH-induced ovulation in hamsters and rats by synthetic analogues of LH-RH. Reproduction. 48(1). 119–124. 9 indexed citations
16.
Cruz, Antonio De la, D.H. Coy, & Andrew V. Schally. (1975). Blockade of the pre ovulatory surge in hamsters by an inhibitory analog of LH-RH. Clinical research. 23(3). 1 indexed citations
17.
Zañartu, J, Jorge M. Rosner, E Guiloff, et al.. (1975). Attempts to programme ovulation with exogenous oestrogens and LH-RH analogue.. BMJ. 2(5970). 527–529. 7 indexed citations
18.
Carr, Denis H., A Gómez-Pan, D. R. Weightman, et al.. (1975). Growth hormone release inhibiting hormone: actions on thyrotrophin and prolactin secretion after thyrotrophinreleasing hormone.. BMJ. 3(5975). 67–69. 45 indexed citations
19.
Mortimer, C. H., Denis H. Carr, T. Lind, et al.. (1974). EFFECTS OF GROWTH-HORMONE RELEASE-INHIBITING HORMONE ON CIRCULATING GLUCAGON, INSULIN, AND GROWTH HORMONE IN NORMAL, DIABETIC, ACROMEGALIC, AND HYPOPITUITARY PATIENTS. The Lancet. 303(7860). 697–701. 217 indexed citations breakdown →
20.
Besser, G. M., C. H. Mortimer, Denis H. Carr, et al.. (1974). Growth Hormone Release Inhibiting Hormone in Acromegaly. BMJ. 1(5904). 352–355. 115 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026